Blood Transfusion Diagnostics Market - Snapshot
Blood transfusion diagnostics are products used to conduct tests before transfusion of blood and blood products from donor to recipient. These products include instruments such as analyzers and centrifuges, and kits & reagents for various tests such as blood grouping and disease screening for donors as well as patients. Blood screening is a major step in the pre-transfusion process. Various instruments, test kits, and reagents based on molecular and serological techniques are used to detect transfusion transmitted infections (TTIs) along with establishing the compatibility of donor and patient blood group before transfusion. The global blood transfusion diagnostics market was valued at US$ 3.0 Bn in 2016 and is projected to expand at a CAGR of 5.9% from 2017 to 2025 to reach US$ 5.5 Bn by 2025.
Increase in shift toward automation in blood banks is likely to benefit blood collection facilities due to reduced turnaround time for test completion and overcoming the shortage of workforce required to conduct the requisite tests. Deployment of automated systems is anticipated to help these facilities to reorganize workflow and increase efficiency. Rise in demand for blood and blood components transfusions owing to large patient population suffering from chronic diseases such as aplastic anemia, sickle cell anemia, and leukemia is the major factor driving the blood transfusion diagnostics market. According to estimates provided by the American Cancer Society, nearly 62,130 new cases of leukemia were reported in the U.S. alone in 2017. According to Centers for Disease Control and Prevention (CDC) estimates, 100,000 people are affected by sickle cell disease in the U.S. each year. Rise in incidence of chronic diseases presents large patient population requiring blood transfusions. This is expected to drive demand for blood transfusions, leading to increase in demand for transfusion diagnostic instruments, kits, and reagents.
There is a shift toward automation of instruments, multiplexing assays, and new techniques for blood grouping and disease screening, delivering high throughput results with reduced turnaround time, and enabling health care providers to analyze multiple samples in short time. In February 2017, Immucor, Inc. announced the launch of MIA FORA NGS FLEX HLA Typing Assay, a new molecular test for blood typing. Increase in government initiatives and implementation of policies regarding blood safety and availability are anticipated to drive demand and consumption of blood transfusion diagnostic test instruments and kits, which in turn is likely to propel the market during the forecast period. In September 2017, the Ministry of Health of Saudi Arabia launched a national campaign named My Blood for My Country along with various protocols for blood transfusion diagnostics in the country. However, shortage of highly skilled technologists for blood transfusion services and decline in blood donation rates across the globe are likely to hamper the growth of the market. Nevertheless, burgeoning needs of blood banks for plasma testing of recovered plasma for infectious disease screening offers significant opportunity for players operating in the global blood transfusion diagnostic market for developing new tests and assays for plasma testing.
The global blood transfusion diagnostics market has been segmented based on product type, application, end-user, and region. In terms of product type, the kits & reagents segment is anticipated to account for major market share, followed by the instruments segment. Increase in blood donations and rise in number of blood transfusion procedures globally are factors contributing to the high consumption of kits & reagents for blood transfusion diagnostics. Based on application, the disease screening segment accounted for the largest market share in 2016 and is expected to gain market share by 2025. Increase in emphasis on disease screening tests owing to rise in incidence of transfusion transmitted infections is likely to augment the segment from 2017 to 2025. In terms of end-user, the blood banks segment held the dominant share in terms of revenue in 2016. The segment is projected to maintain its lead over the other segments during the forecast period. Increase in number of blood banks and blood centers globally is expected to fuel the growth of the market.
Geographically, North America was the leading market in terms of revenue due to high percentage of active and voluntary blood donors in countries such as the U.S. and Canada, increase in number of blood transfusions per year, and various blood transfusion policies being implemented regarding safety and testing of blood for infectious diseases. The market in Asia Pacific is projected to grow at a rapid pace during the forecast period, owing to large patient pool requiring blood transfusions and rise in awareness about disease screening in countries in the region.
Major players in the global blood transfusion diagnostics market include BAG Health Care GmbH, Abbott Laboratories, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., DiaSorin S.p.A., Grifols, S.A., Immucor, Inc., Hologic, Inc., Ortho Clinical Diagnostics, and Quotient Limited.
Blood Transfusion Diagnostics Market - Overview
Blood transfusion diagnostics include instruments such as analyzers and centrifuges, and kits & reagents used for various tests such as blood grouping and disease screening for donors as well as patients. Blood screening is a major step in the pre-transfusion process. The report on the global blood transfusion diagnostics market analyzes the current and future prospects of the market. The report consists of an executive summary that provides information about the products, its segments and sub-segments, along with a market snapshot and comparative analysis by region, in terms of revenue %, for 2016.
A detailed overview of market dynamics, including the drivers, restraints, and opportunities of the blood transfusion diagnostics market, along with Porter’s Five Forces Analysis, of the global market has been provided in this report. Market revenue analysis for all the above mentioned segments and sub segments has been provided for the forecast period from 2017 to 2025, considering 2016 as the base year and 2015 as the historical year, along with compound annual growth rate (CAGR %) for the forecast period from 2017 to 2025. Market share estimations were based on in-depth analysis and study of products, and their features, prices, etc.
This report provides in-depth analysis of the global blood transfusion diagnostics market. Stakeholders of this report include companies engaged in the manufacture of blood transfusion diagnostics. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends, and competition in different regions. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the blood transfusion diagnostics market. Furthermore, the report incorporates market attractiveness analysis by region that depicts the most attractive and significant region in the global market.
The research methodology is a combination of primary and secondary research. Primary research includes information collected via e-mails, and telephonic interviews with key opinion leaders (KOL), and forms the bulk of the research. Secondary research includes information collected from various sources by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.
Based on product type, the global blood transfusion diagnostics market has been segmented into instruments and kits & reagents. In terms of application, the global market has been categorized into blood grouping and disease screening. Disease screening has been classified into molecular disease screening and serological disease screening. Based on end-user, the global blood transfusion diagnostics market has been divided into hospitals, diagnostic laboratories, blood banks, plasma fractionation companies, and others.
In terms of region, the global blood transfusion diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further segmented into major countries and sub-regions such as the U.S., Canada, Germany, the U.K., France, Italy, Spain, Rest of Europe, China, Japan, India, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, Saudi Arabia, South Africa, and Rest of MEA. The report also comprises a list of major players in the market, their SWOT analysis, market share of these players in the blood transfusion diagnostics market, key business strategies, product portfolios, and recent developments. Key market players profiled in this report include Grifols S.A., Immucor Inc., Bio-Rad Laboratories Inc., Abbott, DiaSorin S.p.A., Ortho Clinical Laboratories, Quotient Limited, and F. Hoffman-La Roche Ltd.
The global blood transfusion diagnostics market has been segmented as follows:
- Global Blood Transfusion Diagnostics Market, by Product
- Kits & Reagents
- Global Blood Transfusion Diagnostics Market, by Application
- Blood Grouping
- Disease Screening
- Molecular Disease Screening
- Serological Disease Screening
- Global Blood Transfusion Diagnostics Market, by End-user
- Diagnostic Laboratories
- Blood Banks
- Plasma Fractionation Companies
- Global Blood Transfusion Diagnostics Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
- North America